Disease landscape

Breast Cancer clinical trials

Get alerts when Breast Cancer trials change

4,207 active trials 2,279 recruiting 423 Phase 3 1,358 sponsors 528 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-08-28

What changed in the last 30 days showing 68 of 528 changes on 20 trials

2026-08-28
Withdrawn before enrolling
Trial withdrawn: Other - Protocol moved to Withdrawn
Enrollment reduced: 24 → 0 participants
NCT06982222 Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have… · National Cancer Institute (NCI) · Phase 1
2026-08-22
Trial terminated
Trial terminated: The trial was terminated due to sponsor decision.
Enrollment reduced: 136 → 3 participants
Primary completion moved earlier: 2030-06-01 → 2026-06-24
Completion moved earlier: 2030-06-01 → 2026-06-24
NCT07214662 A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a… · Genentech, Inc. · Phase 1
2026-07-31
Trial terminated
Trial terminated: Sponsor Decision
Primary endpoint(s) modified
Enrollment reduced: 849 → 72 participants
Primary completion moved earlier: 2026-10-31 → 2026-04-30
Completion moved earlier: 2027-07-31 → 2026-06-30
NCT05747794 Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in… · Immutep S.A.S. · Phase 2/3
2026-08-05
Trial terminated
Trial terminated: The study was terminated primarily due to a business decision related to a corporate transaction and was not driven by...
Enrollment reduced: 96 → 8 participants
Primary completion moved earlier: 2029-02-28 → 2026-07-28
Completion moved earlier: 2029-05-31 → 2026-07-28
NCT07408089 Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or… · Boundless Bio, Inc. · Phase 1
2026-08-21
Trial terminated
Trial terminated: Study logistics or limited study population, as defined by the iclusion/exclusion criteria, leading to a poor recruitment
Primary completion moved earlier: 2028-03 → 2026-07-23
Completion moved earlier: 2029-09 → 2026-07-23
NCT06595563 HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for… · Jules Bordet Institute · Phase 2
2026-08-18
Suspended trial terminated
NCT07173101 Clinical Investigation of the Effects of Semiconductor Embedded Therapeutic Garments on… · University of Utah · Phase 2
2026-08-21
Trial terminated
Trial terminated: Difficulties in recruitment
NCT06643455 Mindfulness Intervention for Improving Nutrition in the Digital Kitchen Among Stage I-III… · Fred Hutchinson Cancer Center
2026-08-15
Trial status changed: Recruiting → Withdrawn
Trial withdrawn: No accrual
Enrollment reduced: 100 → 0 participants
Primary completion pushed: 2025-12 → 2025-12-31
Completion moved earlier: 2026-12 → 2025-12-31
NCT06052345 Paclitaxel-induced Polyneuropathy in Breast Cancer: Early Detection, Risk Factors… · Theodoros Foukakis
2026-08-13
Trial status changed: Recruiting → Withdrawn
Trial withdrawn: no patients were able to be enrolled
Enrollment reduced: 30 → 0 participants
Primary completion pushed: 2026-06-30 → 2026-08-10
Completion pushed: 2026-06-30 → 2026-08-10
NCT06610097 TNBC Gut Microbiota During Neoadjuvant Treatment · Scripps Health
2026-08-07
Trial terminated
Trial terminated: Principal Investigator's departure
Enrollment reduced: 60 → 34 participants
Primary completion moved earlier: 2026-06-01 → 2026-04-02
Completion moved earlier: 2026-11-01 → 2026-08-02
NCT07165756 "Mon Parcours de Vie" Localized Breast Cancer: Announcement, Support, Information on the… · Institut de Cancérologie de Lorraine
2026-08-28
Primary completion pushed: 2025-07-30 → 2026-12-30
Completion pushed: 2025-07-30 → 2026-12-30
NCT06299124 A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast… · Regor Pharmaceuticals Inc. · Phase 1
2026-08-27
Primary completion pushed: 2026-11-30 → 2027-03-30
Primary endpoint(s) modified
Enrollment increased: 88 → 176 participants
Completion pushed: 2027-03-30 → 2027-07-31
NCT07310420 A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in… · TerSera Therapeutics LLC · Phase 1
2026-08-14
Primary completion pushed: 2026-06-30 → 2026-10-31
Enrollment closed, study ongoing
Completion pushed: 2027-09-30 → 2028-02-29
NCT06016738 OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced… · Olema Pharmaceuticals, Inc. · Phase 3
2026-08-07
Primary completion pushed: 2026-12 → 2031-12
Enrollment increased: 750 → 2250 participants
Completion pushed: 2026-12 → 2031-12
NCT05232916 Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 +… · Greenwich LifeSciences, Inc. · Phase 3
2026-07-31
Primary completion pushed: 2029-03-30 → 2029-12-18
Primary endpoint(s) modified
Enrollment increased: 500 → 788 participants
Completion pushed: 2030-10-18 → 2031-12-30
Trial arms changed: 3 → 4
NCT06380751 Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6… · AstraZeneca · Phase 3
2026-07-31
Primary completion pushed: 2026-07-06 → 2026-11-11
NCT04784715 Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and… · AstraZeneca · Phase 3
2026-08-26
Primary completion pushed: 2026-08 → 2026-12
Completion pushed: 2026-08 → 2026-12
NCT06067503 Biomarkers to Detect Endocrine Therapy Resistance · University of Wisconsin, Madison · Phase 2
2026-08-13
Primary completion pushed: 2026-09-30 → 2026-12-30
Completion pushed: 2026-12-30 → 2027-03-31
NCT05304962 FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative… · Regor Pharmaceuticals Inc. · Phase 1
2026-08-05
Primary completion pushed: 2026-07 → 2027-09
Completion pushed: 2026-07 → 2027-09
Trial arms changed: 9 → 10
NCT06084481 Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With… · AbbVie · Phase 1
2026-08-26
Primary completion pushed: 2026-09-01 → 2028-09-01
Completion pushed: 2028-12-31 → 2030-12-31
NCT05483491 KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer · Christian Hinrichs · Phase 1

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-08-25 NCT07784036 JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer Chengdu JOYO pharma Co., Ltd. new Phase 3
2026-08-24 NCT07781852 Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and… Lumina Pharmaceuticals Inc new Early Phase 1
2026-08-24 NCT07782814 An Investigation Into Dielectric Testing for the Evaluation and Characterisation of… Zedsen Limited new
2026-08-24 NCT07780955 Multimodal Assessment of Cryotherapy for Paclitaxel-Induced Neuropathy Azienda Sanitaria dell'Alto Adige new
2026-08-24 NCT07781163 Evaluation of the Safety and Efficacy of Single-Port Robot-Assisted Endoscopic… Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine new
2026-08-24 NCT07782866 MindVybe tVNS/APS for Wellbeing in Breast Cancer Survivors The Healing Consciousness Foundation new
2026-08-24 NCT07782801 Creation and Implementation a Method for Breast Reconstruction After Radical Surgery… National Research Oncology and Transplantology Center, Kazakhstan new
2026-08-21 NCT07779967 Alcohol, Breast Cancer, and Metabolism University of Illinois at Urbana-Champaign new
2026-08-20 NCT07776951 Physical Activity and Healthy Aging: Promoting Cardio-metabolic Capacity to Fight Chronic… University of Milan new
2026-08-20 NCT07777289 A TEACH-BACK APPROACH TO INCREASE BREAST CANCER KNOWLEDGE IN WOMEN WITH LOW HEALTH… Buca Seyfi Demirsoy State Hospital new

Active trials by phase

Early Phase 1
44
Phase 1
315
Phase 1/2
250
Phase 2
901
Phase 2/3
34
Phase 3
389
Phase 4
65
Not charted: 2,209 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 4,207

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT06274515 A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies Hoffmann-La Roche Recruiting 2026-08-06
NCT07257484 Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors Weill Medical College of Cornell University Recruiting 2026-07-22
NCT07252726 Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic… Ottawa Hospital Research Institute Recruiting 2026-07-17
NCT07600164 Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer Peking University People's Hospital Recruiting 2026-07-13
NCT07220967 A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement Memorial Sloan Kettering Cancer Center Recruiting 2026-07-10
NCT07695259 Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer Wen-Ming Cao Recruiting 2026-07-10
NCT05753618 Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients… Ottawa Hospital Research Institute Recruiting 2026-07-08
NCT06169371 Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI) University of Illinois at Chicago Recruiting 2026-07-07
NCT05183126 Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With… University of Michigan Rogel Cancer Center Recruiting 2026-07-02
NCT05376878 An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+… City of Hope Medical Center Recruiting 2026-07-01
NCT03096418 Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response University of Wisconsin, Madison Recruiting 2026-06-16
NCT04921137 Evaluating Harms and Benefits of Endocrine Therapy in Patients ≥70 Years of Age With… Ottawa Hospital Research Institute Recruiting 2026-05-28
NCT07578064 A Randomized, Self-controlled Post-marketing Clinical Study on the Comparison of Shengbai… Hongxia Wang Recruiting 2026-05-11
NCT07195344 Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated… Institut Claudius Regaud Recruiting 2026-05-05
NCT07042581 A Study of Revaree Plus in People With Breast Cancer Memorial Sloan Kettering Cancer Center Recruiting 2026-02-06
NCT07308717 Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART)… Memorial Sloan Kettering Cancer Center Recruiting 2025-12-30
NCT07257679 Gentle Touch for Post-Mastectomy Lymphedema I.R.C.C.S. Fondazione Santa Lucia Recruiting 2025-12-02
NCT06934239 A Trial Comparing Screening Mammography With and Without Assistance From Artificial… Jonsson Comprehensive Cancer Center Recruiting 2025-11-26
NCT06230055 Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With… Fudan University Recruiting 2025-11-25
NCT06072807 Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer Weill Medical College of Cornell University Recruiting 2025-11-24
NCT06429761 Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients AstraZeneca Recruiting 2025-11-24
NCT07158164 DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment Rutgers, The State University of New Jersey Recruiting 2025-11-13
NCT06574022 Post-mastectomy Recovery: Comparing Preoperative PECS-II Blocks With Intraoperative… University of Cincinnati Recruiting 2025-11-04
NCT05206331 CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a… Margarita Louise Zuley Recruiting 2025-10-08
NCT06491680 Cardiotoxicity in Breast Cancer Patients Helwan University Recruiting 2025-09-22
See all 4,207 active Breast Cancer trials with filters →

Top sponsors by active trials in this area

Fudan University (136) · Memorial Sloan Kettering Cancer Center (105) · M.D. Anderson Cancer Center (89) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (58) · National Cancer Institute (NCI) (55) · AstraZeneca (53) · Dana-Farber Cancer Institute (49) · Mayo Clinic (49) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (43) · City of Hope Medical Center (42)

Get alerts when Breast Cancer trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free